When considering combination therapy for prostate cancer, it is crucial to consider amplifying antigen-specific CD8+ T cells, efficiently trafficking them by TIME reprogramming, and reinvigorating and sustaining their survival via ICB and cytokines. This evidence concerns the gene CD8A and prostate carcinoma.